Skip to main content

Table 1 Patient characteristics measured at the start of each medication treatment episode

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Baseline covariates (%) ABA ADA ETA INF LEF MTX RIT SSZ-HCQ Total
( N  =  27 ) ( N  =  116 ) ( N  =  113 ) ( N  =  29 ) ( N  =  110 ) ( N  =  183 ) ( N  =  24 ) ( N  =  357 ) ( N  =  959 )
Unique patients 25 113 112 26 98 170 18 302 566
Mean age, years (SD) 60.5 (8.2) 61.0 (9.9) 61.2 (9.7) 57.1 (9.4) 64.5 (11.0) 62.2 (10.6) 62.2 (7.7) 62.3 (10.5) 62.1 (10.3)
Male gender 25 (92.6) 106 (91.4) 108 (95.6) 23 (79.3) 101 (91.8) 167 (91.3) 23 (95.8) 327 (91.6) 880 (91.8)
Medication use six months prior start of treatment episode     
MTX/LEF 18 (66.7) 71 (61.2) 69 (61.1) 20 (69.0) 51 (46.4) 17 (9.3) 12 (50) 145 (40.6) 403 (42.0)
HCQ/SSZ 4 (14.8) 18 (15.5) 19 (16.8) 4 (13.8) 21 (19.1) 68 (37.2) 3 (12.5) 45 (12.6) 182 (19.0)
Oral glucocorticoids 9 (33.3) 43 (37.1) 50 (44.3) 8 (27.6) 39 (35.5) 68 (37.2) 13 (54.2) 117 (32.8) 347 (36.2)
HBV antivirals1 1 (3.7) 5 (4.3) 2 (1.8) 0 (0) 0 (0) 3 (1.6) 0 (0) 12 (3.4) 23 (2.4)
Comorbidities2        
Hepatitis C 5 (18.5) 18 (15.5) 23 (20.4) 7 (24.1) 6 (5.5) 11 (6.1) 6 (25.0) 69 (19.3) 145 (15.1)
COPD 4 (14.8) 13 (11.2) 19 (16.8) 8 (27.6) 20 (18.2) 5 (19.1) 7 (29.2) 65 (18.2) 171 (17.8)
Hypertension 15 (55.6) 65 (56.0) 65 (57.5) 14 (48.3) 76 (69.1) 112 (61.2) 14 (58.3) 236 (66.1) 597 (62.3)
Diabetes mellitus 4 (14.8) 22 (19.0) 19 (16.8) 2 (6.9) 19 (17.3) 50 (27.3) 4 (16.7) 90 (25.2) 210 (21.9)
Solid cancer 2 (7.4) 6 (5.2) 5 (4.4) 2 (6.9) 17 (15.5) 21 (11.5) 2 (8.3) 31 (8.7) 86 (9.0)
  1. 1HBV antivirals - lamivudine, entecavir, tenofovir, telbivudine, adefovir, emtricitabine, emtricitabine/tenofovir; 2defined by International Classification of Diseases, Ninth Revision (ICD-9) codes and measured 12 months prior to the index date. ABA, abatacept; ADA, adalimumab; ETA, etanercept; INF, infliximab; LEF, leflunomide; MTX, methotrexate; RIT, rituximab; SSZ-HCQ, sulfasalazine/hydroxychloroquine; SD, standard deviation; HBV, hepatitis B virus; COPD, chronic obstructive pulmonary disease.